# Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

> **NCT05776134** · — · AVAILABLE · sponsor: **Kite, A Gilead Company**

## Conditions studied

- Mantle Cell Lymphoma
- Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** Brexucabtagene Autoleucel

## Key facts

- **NCT ID:** NCT05776134
- **Lead sponsor:** Kite, A Gilead Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05776134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05776134, "Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05776134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*